Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013

Joseph R. Mikhael, David Dingli, Vivek Roy, Craig B. Reeder, Francis K. Buadi, Suzanne R. Hayman, Angela Dispenzieri, Rafael Fonseca, Taimur Sher, Robert A. Kyle, Yi Lin, Stephen J. Russell, Shaji Kumar, P. Leif Bergsagel, Steven R. Zeldenrust, Nelson Leung, Matthew T. Drake, Prashant Kapoor, Stephen M. Ansell, Thomas E. WitzigJohn A. Lust, Robert J. Dalton, Morie A. Gertz, Keith Stewart, S. Vincent Rajkumar, Asher Chanan-Khan, Martha Q. Lacy

Research output: Contribution to journalArticle

286 Scopus citations

Abstract

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. There has been a veritable revolution in this disease during the past decade, with dramatic improvements in our understanding of its pathogenesis, the development of several novel agents, and a concomitant doubling in overall survival. Because multiple myeloma is a complex and wideranging disorder, its management must be guided by disease- and patient-related factors; emerging as one of the most influential factors is risk stratification, primarily based on cytogenetic features. A risk-adapted approach provides optimal therapy to patients, ensuring intense therapy for aggressive disease and minimizing toxic effects, providing sufficient but less intense therapy for low-risk disease. This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial.

Original languageEnglish (US)
Pages (from-to)360-376
Number of pages17
JournalMayo Clinic proceedings
Volume88
Issue number4
DOIs
StatePublished - Apr 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013'. Together they form a unique fingerprint.

  • Cite this